Physician

Chaim Y. Mandelbaum, M.D.

According to 2025 Medicare claims, Chaim Mandelbaum, M.D. (NPI: 1215075908) practices interventional pain management (ipm) in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Kings, NY. This provider's primary affiliated billing organization is COMPREHENSIVE PAIN MANAGEMENT AND SPINE CARE, PLLC (NPI: 1346714664) and primary practice location at 10038-5162.

Mandelbaum's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 337 traditional Medicare patients, billed 32,766 HCPCS/CPT codes, and received $659,332 in Medicare payments. The top billing code was G0481 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 6,802 prescription claims across 474 beneficiaries totaling $1,007,542 in drug costs, led by Oxycontin (Oxycodone Hcl). 2021 DME data shows 11 claims. Open Payments data shows 98 records totaling $1,798. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have declined steadily, from $1,988,450 to $1,007,542. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $2,598 to $735.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	659	24,044	$654,576
2016	697	35,577	$791,622
2017	695	55,571	$1,014,433
2018	683	52,554	$917,452
2019	593	50,804	$874,894
2020	457	56,167	$841,895
2021	418	42,275	$925,204
2022	411	42,400	$927,066
2023	374	47,296	$810,861
2024	337	32,766	$659,332

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	684	11,244	$1,988,450
2016	637	7,695	$1,399,930
2017	659	7,033	$1,277,506
2018	640	6,356	$1,166,386
2019	630	8,414	$1,458,609
2020	560	9,996	$1,418,542
2021	511	8,861	$1,328,668
2022	464	7,649	$1,338,475
2023	439	7,326	$1,223,070
2024	474	6,802	$1,007,542

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$3,776
2016	N/R	17	$1,732
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$133
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	240	949	$153
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	321	2,758	$98
80307	Testing for presence of drug, by chemistry analyzers	238	943	$39
20552	Injection of trigger points, 1-2 muscles	47	57	$36
J0588	Injection, incobotulinumtoxin a, 1 unit	53	24,255	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Oxycontin	Oxycodone Hcl	159	4,713	$120,906
Relistor	Methylnaltrexone Bromide	48	1,440	$119,113
Diclofenac Sodium	Diclofenac Sodium	364	11,495	$100,163
Xtampza Er	Oxycodone Myristate	108	3,190	$80,657
Horizant	Gabapentin Enacarbil	87	2,790	$60,171

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	98	$1,798	Salix Pharmaceuticals, a division of Bausch Health US, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chaim Y. Mandelbaum, M.D.?

Tedicare shows public-source Medicare data for Chaim Y. Mandelbaum, M.D. (NPI 1215075908), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chaim Y. Mandelbaum, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chaim Y. Mandelbaum, M.D.?

Chaim Y. Mandelbaum, M.D. is linked to COMPREHENSIVE PAIN MANAGEMENT AND SPINE CARE, PLLC (billing NPI 1346714664) in the available physician profile data.

Does Chaim Y. Mandelbaum, M.D. have Open Payments data?

Chaim Y. Mandelbaum, M.D. has 98 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.